Recombinomics, Inc. Founder and President, Henry L Niman earned a PhD at the University of Southern California in 1978. He took a postdoctoral position at Scripps Clinic and Research Foundation where he developed monoclonal anti-body technology. In 1982, he developed the flu monoclonal antibody, which is widely used throughout the pharmaceutical, biotech, and research industries. Some of his monoclonal antibodies were distributed worldwide to researchers by the National Cancer Institute. This technology was used to form ProgenX, a cancer diagnostic company that became Ligand Pharmaceuticals.
Dr. Niman subsequently identified protein expression patterns at the University of Pittsburgh. More recently, he became interested in infectious diseases while at Harvard Medical School. He then founded Recombinomics and discovered how viruses rapidly evolve.